|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Apr 1, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets | |||||||||||||||
| Cash | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Accounts receivable | |||||||||||||||
| Accrued revenue | |||||||||||||||
| Prepaid expenses and other assets | |||||||||||||||
| Total current assets | |||||||||||||||
| Restricted cash | |||||||||||||||
| Property and equipment, net | |||||||||||||||
| Investments | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||
| Current liabilities | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued expenses | |||||||||||||||
| Deferred revenue | |||||||||||||||
| Short term insurance financing | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Stockholders’ equity | |||||||||||||||
| Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares authorized; 73,449 shares issued and outstanding as of June 30, 2026 and December 31, 2025. | |||||||||||||||
| Common stock, $0.00001 par value, 100,000,000 shares authorized; 18,541,651 and 11,418,183 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively. | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Total stockholders’ equity | |||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||
Loading...
